Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 11, 2008, Pages 3605-3612

  Tepel, Martin ^a   Hopfenmueller, Werner ^a   Scholze, Alexandra ^a   Maier, Alexandra ^a   Zidek, Walter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Calcium channel blocker; Cardiovascular risk; Chronic kidney disease

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GERMANY; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 54149104096     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn304     Document Type: Article

References (19)

1. Locatelli F, Bommer J, London GM et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16: 459-468
2. Martins Castro MC, Luders C, Elias RM et al. High-efficiency short daily haemodialysis - morbidity and mortality rate in a long-term study. Nephrol Dial Transplant 2006; 21: 2232-2238
3. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K et al. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006; 21: 1257-1262
4. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154
5. Tepel M. Oxidative stress: does it play a role in the genesis of essential hypertension and hypertension of uraemia. Nephrol Dial Transplant 2003; 18: 1439-1442
6. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
7. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-1964
8. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906
9. Julius S, Kjeldsen SE, Weber M et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031
10. Tepel M, Van Der Giet M, Park A et al. Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond) 2002; 103: 511-515
11. Kestenbaum B, Gillen DL, Sherrard DJ et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61: 2157-2164
12. Wanner C, Krane V, Marz W et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
13. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051
14. Tomita J, Kimura G, Inoue T et al. Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 1995; 25: 405-412
15. Foley RN, Parfrey PS, Harnett JD et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385
16. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817
17. Li Z, Lacson E Jr, Lowrie EG et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: 606-615
18. Kalantar-Zadeh K, Kovesdy CP, Derose SF et al. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol 2007; 3: 493-506
19. Aslam S, Santha T, Leone A et al. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006; 70: 2109-2115